Publicaciones científicas más relevantes

• DM Geynisman; M Burotto; C Porta; C Suarez; MT Bourlon; V Del Tejo; EX Du; X Yang; SR Sendhil; KA Betts; S Huo. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma. Oncologist.28 – 1, pp. 72 – 79. 18/01/2023. ISSN 1549490X. DOI: 10.1093/oncolo/oyac186
• Matthew S. Ernst; Vishal Navani; J. Connor Wells; Frede Donskov; Naveen Basappa; Chris Labaki; Sumanta K. Pal; Luis Meza; Lori A. Wood; D. Scott Ernst; Bernadett Szabados; Rana R. McKay; Francis Parnis; Cristina Suarez; Takeshi Yuasa; Aly-Khan Lalani; Ajjai Alva; Georg A Bjarnason; Toni K. Choueiri; Daniel Y.C. Henga. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.  European Urology. 26/01/2023. ISSN 0302-2838. DOI: 10.1016/j.eururo.2023.01.001
• Suarez, Cristina; Vieito, Maria; Valdivia, Augusto; Gonzalez, Macarena; Carles, Joan. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors. Med Sci (Basel, Switzerland). 11 – 3, 01/01/2023. ISSN 2076-3271
• Pestana RC, Serrano C.  Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database. Front Oncol. 2023 Jan 18;12:1079909. doi: 10.3389/fonc.2022.1079909. eCollection 2022.
• RJ Motzer; M Schmidinger; M Eto; C Suarez; R Figlin; Y Liu; R Perini; Y Zhang; DY. Heng. LITESPARK-011: Belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncol.08/02/2023. ISSN 1479-6694. DOI: 10.2217/fon-2022-0802
• Yu, Evan Y.; Piulats, Josep M.; Gravis, Gwenaelle; Fong, Peter C. C.; Todenhoefer, Tilman; Laguerre, Brigitte; Arranz, Jose A.; Oudard, Stephane; Massard, Christophe; Heinzelbecker, Julia; Nordquist, Luke T.; Carles, Joan; Kolinsky, Michael P.; Augustin, Marinela; Gurney, Howard; Tafreshi, Ali; Li, Xin Tong; Qiu, Ping; Poehlein, Christian H.; Schloss, Charles; de Bono, Johann S.Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study (vol 83, pg 15, 2023). Eur Urol. 83 – 3, pp. E87 – E87. 16/02/2023. ISSN 0302-2838, ISSN 1873-7560
• Moreno V, Vieito M, Sepulveda JM, Galvao V, Hernández-Guerrero T, Doger B, Saavedra O, Carlo-Stella C, Michot JM, Italiano A, Magagnoli M, Carpio C, Pinto A, Sarmiento R, Amoroso B, Aronchik I, Filvaroff E, Hanna B, Wei X, Nikolova Z, Braña I. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. Nat Commun. 2023 Mar 13;14(1):1359. doi: 10.1038/s41467-023-36976-1. PMID: 36914652 Free PMC article. Clinical Trial.
• He W, Xu L, Ding J, Song L, Yang W, Klooster I, Pilco-Janeta DF, Serrano C, Fang H, Jiang G, Wang X, Yu J, Ou WB. Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors. Biochim Biophys Acta Mol Basis Dis. 2023 Jun;1869(5):166690. doi: 10.1016/j.bbadis.2023.166690. Epub 2023 Mar 13.
• Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O’Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 May;185:178-215. doi: 10.1016/j.ejca.2023.02.018. Epub 2023 Mar 3. PMID: 37003085.
• Moreno V, Vieito M, Sepulveda JM, Galvao V, Hernández-Guerrero T, Doger B, Saavedra O, Carlo-Stella C, Michot JM, Italiano A, Magagnoli M, Carpio C, Pinto A, Sarmiento R, Amoroso B, Aronchik I, Filvaroff E, Hanna B, Wei X, Nikolova Z, Braña I. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. Nat Commun. 2023 Mar 13;14(1):1359. doi: 10.1038/s41467-023-36976-1. PMID: 36914652 Free PMC article. Clinical Trial.
• Pérez-Fidalgo JA, Ortega E, Ponce J, Redondo A, Sevilla I, Valverde C, Isern Verdum J, de Alava E, Galera López M, Marquina G, Sebio A. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS). Ther Adv Med Oncol. 2023 Mar 28;15:17588359231157645. doi: 10.1177/17588359231157645. PMID: 37007636; PMCID: PMC10052607.
• T Powles; M Kockx; A Rodriguez-Vida; I Duran; SJ Crabb; MS Van Der Heijden; B Szabados; AF Pous; G Gravis; UA Herranz; A Protheroe; A Ravaud; D Maillet; MJ Mendez; C Suarez; M Linch; A Prendergast; PJ van Dam; D Stanoeva; S Daelemans; S Mariathasan; JS Tea; K Mousa; R Banchereau; D Castellano. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 29 – 12, pp. 3271. 21/03/2023. DOI: 10.1038/s41591-019-0628-7
• C Loo Gan; J Huang; E Pan; W Xie; AL Schmidt; C Labaki; L Meza; G Bouchard; H Li; F Jackson-Spence; C Sánchez-Ruiz; T Powles; SA Kumar; N Weise; WA Hall; BS Rose; B Beuselinck; C Suarez; SK Pal; TK Choueiri; DYC Heng; RR. McKay. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 6 – 2, pp. 204 – 211. 01/04/2023. DOI: 10.1016/j.euo.2022.10.004
• Serrano C, Bauer S, Gómez-Peregrina D, Kang YK, Jones RL, Rutkowski P, Mir O, Heinrich MC, Tap WD, Newberry K, Grassian A, Shi H, Bialick S, Schöffski P, Pantaleo MA, von Mehren M, Trent JC, George S. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.  Ann Oncol. 2023 Jul;34(7):615-625. doi: 10.1016/j.annonc.2023.04.006. Epub 2023 Apr 25.
• Ruiz-Demoulin S, Trenquier E, Dekkar S, Deshayes S, Boisguérin P, Serrano C, de Santa Barbara P, Faure S. LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib. Int J Mol Sci. 2023 Apr 12;24(8):7138. doi: 10.3390/ijms24087138.
• Carles, Joan; Medina-Lopez, Rafael A.; Puente, Javier; Gomez-Ferrer, Alvaro; Nebra, Javier Casas; Medina, Maria Isabel Saez; Ribal, Maria J.; Antolin, Alfredo Rodriguez; Alvarez-Ossorio, Jose Luis; Novo, Jose Francisco Suarez; Agut, Cristina Moretones; Srinivasan, Shankar; Ortiz, Jorge; Fizazi, Karim. Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis. Fut Oncol. 19 – 12, pp. 819 – 828. Fut Med LTD, 24/05/2023. ISSN 1479-6694, ISSN 1744-8301
• Morales-Barrera, Rafael; Villacampa, Guillermo; Vidal, Natalia; Figols, Mariona; Giner, Julia; Bonfill, Teresa; Suarez, Cristina; Diaz, Nely; Mateo, Joaquin; Gonzalez, Macarena; Domenech, Montserrat; Puente, Javier; Carles, Joan. Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment. Clin & Trans Oncol. 25 – 12, pp. 3556 – 3564. SPRINGER INT PUBL AG, 22/05/2023. ISSN 1699-048X, ISSN 1699-3055
• C Suárez; JMG Larkin; P Patel; BP Valderrama; A Rodriguez-Vida; H Glen; F Thistlethwaite; C Ralph; G Srinivasan; MJ Mendez-Vidal; R Hartmaier; A Markovets; A Prendergast; B Szabados; K Mousa; T Powles. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO). J Clin Oncol.41 – 14, pp. 2493 – 2502. 10/05/2023. ISSN 2394-6520. DOI: 10.1200/JCO.22.01414
• Hernando-Calvo A, Mirallas O, Marmolejo D, Saavedra O, Vieito M, Assaf Pastrana JD, Aguilar S, Bescós C, Lorente J, Giralt J, Benavente S, Temprana-Salvador J, Alberola M, Dienstmann R, Garralda E, Felip E, Villacampa G, Brana I. Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients. Oral Oncol. 2023 May;140:106364. doi: 10.1016/j.oraloncology.2023.106364. Epub 2023 Mar 28. PMID: 36989964 Free article.
• TK Choueiri; T Powles; L Albiges; M Burotto; C Szczylik; B Zurawski; E Yanez Ruiz; M Maruzzo; A Suarez Zaizar; LE Fein; FA Schutz; DYC Heng; F Wang; F Mataveli; YL Chang; M van Kooten Losio; C Suarez; RJ Motzer. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N. Engl J Med.388 – 19, pp. 1767 – 1778. 11/05/2023. DOI: 10.1056/NEJMoa2212851
• AB McGregor; DM Geynisman; M Burotto; C Suárez; MT Bourlon; PC Barata; S Gulati; S Huo; F Ejzykowicz; SI Blum; V Del Tejo; M Hamilton; JR May; EX Du; A Wu; P Kral; C Ivanescu; A Chin; KA Betts; CH Lee; TK Choueiri; D Cella; C Porta. Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. Eur. Urol. Oncol.6 – 3, pp. 339 – 348. 01/06/2023. ISSN 2588-9311. DOI: 10.1016/j.euo.2023.01.012
• Suárez C, Vieito M, Valdivia A, González M, Carles J. Med Sci (Basel). Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors. 2023 Jun 30;11(3):46. doi: 10.3390/medsci11030046. PMID: 37489462 Free PMC article. Review.
• Agarwal, N.; Azad, A. A.; Carles, J. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial (vol 402, pg 291, 2023). LANCET. 402 – 10398, pp. 290 – 290. 22/07/2023. ISSN 0140-6736, ISSN 1474-547X
• MS Ernst; V Navani; JC Wells; F Donskov; N Basappa; C Labaki; SK Pal; L Meza; LA Wood; DS Ernst; B Szabados; RR McKay; F Parnis; C Suarez; T Yuasa; AK Lalani; A Alva; GA Bjarnason; TK Choueiri; DYC Heng. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur. Urol  2023; 84 (1): 109 – 116. 07/2023. DOI: 10.1016/j.eururo.2023.01.001
• Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Harrow B, Becker C, Reichmann W, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S; INTRIGUE investigators. Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. Eur J Cancer. 2023 Oct;192:113245. doi:  10.1016/j.ejca.2023.113245. Epub 2023 Jul 20. PMID: 37598656 Free article. Clinical Trial.
• SK Pal; L Albiges; P Tomczak; C Suárez; MH Voss; G de Velasco; J Chahoud; A Mochalova; G Procopio; H Mahammedi; F Zengerling; C Kim; T Osawa; M Angel; S Gupta; O Khan; G Bergthold; B Liu; M Kalaitzidou; M Huseni; C Scheffold; T Powles; TK Choueiri. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomized, open-label, phase 3 trial. Lancet, 402, pp. 185 – 195. 15/07/2023. DOI: 10.1016/S0140-6736(23)00922-4.
• Serrano C, Martín-Broto J, Asencio-Pascual JM, López-Guerrero JA, Rubió-Casadevall J, Bagué S, García-Del-Muro X, Fernández-Hernández JÁ, Herrero L, López-Pousa A, Poveda A, Martínez-Marín V. 2023 GEIS Guidelines for gastrointestinal stromal tumors.  Ther Adv Med Oncol. 2023 Aug 24;15:17588359231192388. doi: 10.1177/17588359231192388. eCollection 2023. PMID: 37655207 Free PMC article. Review.
• Laurence Albiges; Howard Gurney; Vagif Atduev; Cristina Suarez; Miguel A Climent; David Pook; Piotr Tomczak; Philippe Barthelemy; Jae Lyun Lee; Viktor Stus; Thomas Ferguson; Erhan Gokmen; Louis Lacombe; Craig Gedye; Rodolfo F Perini; Manish Sharma; Xiang Peng; Lee Chung-Han. Pembrolizumab plus lenvatinib as first-line therapy for advanced nonclear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. The Lancet. 24 – 8, pp. 881 – 891. 01/08/2023. DOI: 10.1016/S1470-2045(23)00276-0
• Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. PMID: 37272516 Clinical Trial.
• Tabernero J, Bedard PL, Bang YJ, Vieito M, Ryu MH, Fagniez N, Chadjaa M, Soufflet C, Masson N, Gazzah A. Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens. Cancer Res Commun. 2023 Aug 28;3(8):1662-1671. doi: 10.1158/2767-9764.CRC-23-0284. eCollection 2023 Aug. PMID: 37645622 Free PMC article. Clinical Trial.
• Di Vito A, Ravegnini G, Gorini F, Aasen T, Serrano C, Benuzzi E, Coschina E, Monesmith S, Morroni F, Angelini S, Hrelia P. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib. Pharmacol Ther. 2023  Aug; 248:108475. doi: 10.1016/j.pharmthera.2023.108475. Epub 2023 Jun 10.
• Martin-Broto J, Valverde C, Hindi N, Vincenzi B, Martinez-Trufero J, Grignani G, Italiano A, Lavernia J, Vallejo A, Tos PD, Le Loarer F, Gonzalez-Campora R, Ramos R, Hernández-Jover D, Gutierrez A, Serrano C, Monteagudo M, Letón R, Robledo M, Moura DS, Martin-Ruiz M, López-Guerrero JA, Cruz J, Fernandez-Serra A, Blay JY, Fumagalli E, Martinez-Marin V. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Mol Cancer. 2023 Aug 9;22(1):127.
• Carreras, Maria-Josep; Tomas-Guillen, Elena; Farriols, Anna; Renedo-Miro, Berta; Valdivia, Carolina; Vidal, Jana; Saura, Cristina; Carles, Joan; Felip, Enriqueta; Gorgas, Maria-Queralt; Tabernero, Josep; Monterde, Josep. Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study. Curr Oncol. 30 – 9, pp. 7984 – 8004. MDPI, 01/09/2023. ISSN 1198-0052, ISSN 1718-7729
• Pook, David; Geynisman, Daniel M.; Carles, Joan; de Braud, Filippo; Joshua, Anthony M.; Perez-Gracia, Jose Luis; Perez, Casilda Llacer; Shin, Sang Joon; Fang, Bruno; Barve, Minal; Maruzzo, Marco; Bracarda, Sergio; Kim, Miso; Kerloeguen, Yannick; Gallo, Jorge Daniel; Maund, Sophia L.; Harris, Adam; Huang, Kuan-Chieh; Poon, Victor; Sutaria, Dhruvitkumar S.; Gurney, Howard. A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer. Clin Can Res 2023; 29 – 17, AMER ASSOC CANCER RESEARCH, 01/09/2023. ISSN 1078-0432, ISSN 1557-3265
• Serrano C, Álvarez R, Carrasco JA, Marquina G, Martínez-García J, Martínez-Marín V, Sala MÁ, Sebio A, Sevilla I, Martín-Broto J. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022). Clin Transl Oncol. 2023 Sep;25(9):2707-2717. doi: 10.1007/s12094-023-03177-7. Epub 2023 May 2. PMID: 37129716 Free PMC article.
• Giacomo Nuvola; Veronica Mollica; Francesco Massari; Cristina Suárez. SEP The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors.  Future Medicine. 18/09/2023. DOI: 10.2217/imt-2023-021
• Vieito M, Moreno V, Spreafico A, Brana I, Wang JS, Preis M, Hernández T, Genta S, Hansen AR, Doger B, Galvao V, Lenox L, Brown RJ, Kalota A, Mehta J, Pastore F, Patel B, Mistry P, Gu J, Lauring J, Patel MR. Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.  Clin Cancer Res. 2023 Sep 15;29(18):3592-3602. doi: 10.1158/1078-0432.CCR-23-0092. PMID: 37491846 Clinical Trial.
• Hernando-Calvo A, Vila-Casadesús M, Bareche Y, Gonzalez-Medina A, Abbas-Aghababazadeh F, Lo Giacco D, Martin A, Saavedra O, Brana I, Vieito M, Fasani R, Stagg J, Mancuso F, Haibe-Kains B, Han M, Berche R, Pugh TJ, Mirallas O, Jimenez J, Gonzalez NS, Valverde C, Muñoz-Couselo E, Suarez C, Diez M, Élez E, Capdevila J, Oaknin A, Saura C, Macarulla T, Carles Galceran J, Felip E, Dienstmann R, Bedard PL, Nuciforo P, Seoane J, Tabernero J, Garralda E, Vivancos A. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials.  Med. 2023 Oct 13;4(10):710-727.e5. doi: 10.1016/j.medj.2023.07.006. Epub 2023 Aug 11. PMID: 37572657 Free article.
• Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, Tosi D, Park C, Gomez-Roca C, Joly Lobbedez F, Castellano D, Morales-Barrera R, Moreno-Candilejo I, Fléchon A, Yuen K, Rishipathak D, DuPree K, Young F, Michielin F, Shemesh CS, Steinberg EE, Williams P, Lee JL. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma). Clin Cancer Res. 2023 Nov 1;29(21):4373-4384.
• Kokkali S, Georgaki E, Mandrakis G, Valverde C, Theocharis S. Genomic Profiling and Clinical Outcomes of Targeted Therapies in Adult Patients with Soft Tissue Sarcomas. Cells. 2023 Nov 15;12(22):2632. doi: 10.3390/cells12222632. PMID: 37998367; PMCID: PMC10670373.
• Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol. 2023 Nov 14:JCO2300339. doi: 10.1200/JCO.23.00339.
• Serrano, Cesar; Rothschild, Sara; Villacampa, Guillermo; Heinrich, Michael C; George, Suzanne; Blay, Jean-Yves; Sicklick, Jason K; Schwartz, Gary K; Rastogi, Sameer; Jones, Robin L; Rutkowski, Piotr; Somaiah, Neeta; Navarro, Victor; Evans, Denisse; Trent, Jonathan C. Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors. Nat Med 2023; 29 (11): 2689 – 2692
• Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P.; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschaebitz, Stefanie; Oldenburg, Jan; Ye, Dingwei; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Laird, A. Douglas; Zohren, Fabian; Agarwal, Neeraj. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. Nature Portfolio, 04/12/2023. ISSN 1078-8956, ISSN 1546-170X
• Font A, Mellado B, Climent MA, Virizuela JA, Oudard S, Puente J, Castellano D, González-Del-Alba A, Pinto A, Morales-Barrera R, Rodriguez-Vida A, Fernandez PL, Teixido C, Jares P, Aldecoa I, Gibson N, Solca F, Mondal S, Lorence RM, Serra J, Real FX. Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1). Br J Cancer. 2023 Dec 15. doi: 10.1038/s41416-023-02513-6.
• Hindi N, Razak A, Rosembaum E, Jonczak E, Hamacher R, Rutkowski P, Bhadri VA, Skryd A, Brahmi M, Alshibany A, Jagodzinska-Mucha P, Bauer S, Connolly E, Gelderblom H, Boye K, Henon C, Bae S, Bogefors K, Vincenzi B, Martinez-Trufero J, Lopez-Martin JA, Redondo A, Valverde C, Blay JY, Moura DS, Gutierrez A, Tap W, Martin-Broto J. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry. ESMO Open. 2023 Dec;8(6):102045.
• Sánchez JC, Picola N, Rodriguez-Vida A, Costa M, Castañeda DM, Márquez MP, Rodriguez JM, Gaya JM, Bravo A, Buisan O, Servian P, Suarez JF, Felip MM, Caparrós MJR, Asensio AA, Vilaseca A. Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients. Cancer Med. 2023 Dec;12(24):21969-21977.